Monoclonal antibodies for asthma and chronic obstructive pulmonary disease

Bibliography

• Makris D, Lazarou S, Alexandrakis M, Tc2 response at the onset of copd exacerbations. Chest J 2008;134:483-8
   PubMed Web of Science ®Google Scholar
• He J-Q, Foreman MG, Shumansky K, Associations of il6 polymorphisms with lung function decline and copd. Thorax 2009;64:698-704
   PubMed Web of Science ®Google Scholar
• Lotvall J, Akdis CA, Bacharier LB, Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. J Allergy Clin Immunol 2011;127:355-60
   PubMed Web of Science ®Google Scholar
• Ckless K, Hodgkins SR, Ather JL, Epithelial, dendritic, and CD4+ t cell regulation of and by reactive oxygen and nitrogen species in allergic sensitization. Biochim Biophys Acta 2011;1810:1025-34
   PubMed Web of Science ®Google Scholar
• Kon OM, Sihra BS, Loh LC, The effects of an anti-cd4 monoclonal antibody, keliximab, on peripheral blood CD4+ t-cells in asthma. Eur Respir J 2001;18:45-52
   PubMed Web of Science ®Google Scholar
• Russell SM, Keegan AD, Harada N, Interleukin-2 receptor gamma chain: a functional component of the interleukin-4 receptor. Science 1993;262:1880-3
   PubMed Web of Science ®Google Scholar
• Waldmann TA. The interleukin-2 receptor. J Biol Chem 1991;266:2681-4
   PubMed Web of Science ®Google Scholar
• Corrigan CJ, Hartnell A, Kay AB. T lymphocyte activation in acute severe asthma. Lancet 1988;1:1129-32
   PubMed Web of Science ®Google Scholar
• Busse WW, Israel E, Nelson HS, Daclizumab improves asthma control in patients with moderate to severe persistent asthma: a randomized, controlled trial. Am J Respir Crit Care Med 2008;178:1002-8
   PubMed Web of Science ®Google Scholar
• Allakhverdi Z, Comeau MR, Smith DE, CD34+ hemopoietic progenitor cells are potent effectors of allergic inflammation. J Allergy Clin Immunol 2009;123:472-8; e471
   PubMed Web of Science ®Google Scholar
• Kouro T, Takatsu K. Il-5- and eosinophil-mediated inflammation: from discovery to therapy. Int Immunol 2009;21:1303-9
   PubMed Web of Science ®Google Scholar
• Bousquet J, Chanez P, Lacoste JY, Eosinophilic inflammation in asthma. N Engl J Med 1990;323:1033-9
   PubMed Web of Science ®Google Scholar
• Romagnoli M, Vachier I, Tarodo de la Fuente P, Eosinophilic inflammation in sputum of poorly controlled asthmatics. Eur Respir J 2002;20:1370-7
   PubMed Web of Science ®Google Scholar
• Takatsu K, Nakajima H. Il-5 and eosinophilia. Curr Opin Immunol 2008;20:288-94
   PubMed Web of Science ®Google Scholar
• Hertz M, Mahalingam S, Dalum I, Active vaccination against il-5 bypasses immunological tolerance and ameliorates experimental asthma. J Immunol 2001;167:3792-9
   PubMed Web of Science ®Google Scholar
• Molfino NA, Gossage D, Kolbeck R, Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor. Clini Exp Allergy 2012;42:712-37
   PubMed Web of Science ®Google Scholar
• Egan RW, Athwahl D, Chou CC, Inhibition of pulmonary eosinophilia and hyperreactivity by antibodies to interleukin-5. Int Arch Allergy Immunol 1995;107:321-2
   PubMed Web of Science ®Google Scholar
• Singh AD, Sanderson CJ. Anti-interleukin 5 strategies as a potential treatment for asthma. Thorax 1997;52:483-5
   PubMed Web of Science ®Google Scholar
• Mauser PJ, Pitman A, Witt A, Inhibitory effect of the trfk-5 anti-il-5 antibody in a guinea pig model of asthma. Am Rev Respir Dis 1993;148:1623-7
   PubMed Web of Science ®Google Scholar
• Mauser PJ, Pitman AM, Fernandez X, Effects of an antibody to interleukin-5 in a monkey model of asthma. Am J Respir Crit Care Med 1995;152:467-72
   PubMed Web of Science ®Google Scholar
• Greenfeder S, Umland S, Cuss F, Th2 cytokines and asthma – the role of interleukin-5 in allergic eosinophilic disease. Respir Res 2001;2:71-9
   PubMed Web of Science ®Google Scholar
• Kips JC, O'Connor BJ, Langley SJ, Effect of sch55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med 2003;167:1655-9
   PubMed Web of Science ®Google Scholar
• Castro M, Mathur S, Hargreave F, Reslizumab for poorly controlled, eosinophilic asthma. Am J Respir Crit Care Med 2011;184:1125-32
   PubMed Web of Science ®Google Scholar
• Hart TK, Cook RM, Zia-Amirhosseini P, Preclinical efficacy and safety of mepolizumab (sb-240563), a humanized monoclonal antibody to il-5, in cynomolgus monkeys. J Allergy Clin Immunol 2001;108:250-7
   PubMed Web of Science ®Google Scholar
• Leckie MJ. Anti-interleukin-5 monoclonal antibodies: preclinical and clinical evidence in asthma models. Am J Respir Med 2003;2:245-59
   PubMedGoogle Scholar
• Flood-Page P, Menzies-Gow A, Phipps S, Anti-il-5 treatment reduces deposition of ecm proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest 2003;112:1029-36
   PubMed Web of Science ®Google Scholar
• Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 2003;167:199-204
   PubMed Web of Science ®Google Scholar
• Flood-Page P, Swenson C, Faiferman I, A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 2007;176:1062-71
   PubMed Web of Science ®Google Scholar
• Buttner C, Lun A, Splettstoesser T, Monoclonal anti-interleukin-5 treatment suppresses eosinophil but not t-cell functions. Eur Respir J 2003;21:799-803
   PubMed Web of Science ®Google Scholar
• Haldar P, Brightling CE, Hargadon B, Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009;360:973-84
   PubMed Web of Science ®Google Scholar
• Nair P, Pizzichini MM, Kjarsgaard M, Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009;360:985-93
   PubMed Web of Science ®Google Scholar
• Pavord ID, Korn S, Howarth P, Mepolizumab for severe eosinophilic asthma (dream): a multicentre, double-blind, placebo-controlled trial. Lancet 2012;380:651-9
   PubMed Web of Science ®Google Scholar
• Kolbeck R, Kozhich A, Koike M, Medi-563, a humanized anti–il-5 receptor alpha mab with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol 2010;125:1344-53; e1342
   PubMed Web of Science ®Google Scholar
• Busse WW, Katial R, Gossage D, Safety profile, pharmacokinetics, and biologic activity of medi-563, an anti–il-5 receptor alpha antibody, in a phase i study of subjects with mild asthma. J Allergy Clin Immunol 2010;125:1237-44; e1232
   PubMed Web of Science ®Google Scholar
• Molfino NA, Nowak R, Silverman RA, Reduction in the number and severity of exacerbations following acute severe asthma: results of a placebo-controlled, randomized clinical trial with benralizumab. Am J Respir Crit Care Med 2012;185:A2753
   Google Scholar
• Antoniu SA. Cytokine antagonists for the treatment of asthma: progress to date. BioDrugs 2009;23:241-51
   PubMed Web of Science ®Google Scholar
• Andrews AL, Holloway JW, Holgate ST, Davies DE. Il-4 receptor alpha is an important modulator of il-4 and il-13 receptor binding: implications for the development of therapeutic targets. J Immunol 2006;176:7456-61
   PubMed Web of Science ®Google Scholar
• Andrews AL, Nasir T, Bucchieri F, Il-13 receptor alpha 2: a regulator of il-13 and il-4 signal transduction in primary human fibroblasts. J Allergy Clin Immunol 2006;118:858-65
   PubMed Web of Science ®Google Scholar
• Steinke JW, Borish L. Th2 cytokines and asthma. Interleukin-4: its role in the pathogenesis of asthma, and targeting it for asthma treatment with interleukin-4 receptor antagonists. Respir Res 2001;2:66-70
   PubMed Web of Science ®Google Scholar
• Sommer M, Eismann U, Gerth J, Stein G. Interleukin 4 co-stimulates the pdgf-bb- and bfgf-mediated proliferation of mesangial cells and myofibroblasts. Nephron 2002;92:868-82
   PubMedGoogle Scholar
• Ramalingam TR, Pesce JT, Sheikh F, Unique functions of the type ii interleukin 4 receptor identified in mice lacking the interleukin 13 receptor [alpha]1 chain. Nat Immunol 2008;9:25-33
   PubMed Web of Science ®Google Scholar
• Leonard C, Tormey V, Burke C, Poulter LW. Allergen-induced cytokine production in atopic disease and its relationship to disease severity. Am J Respir Cell Mol Biol 1997;17:368-75
   PubMedGoogle Scholar
• Shi HZ, Xiao CQ, Zhong D, Effect of inhaled interleukin-5 on airway hyperreactivity and eosinophilia in asthmatics. Am J Respir Crit Care Med 1998;157:204-9
   PubMed Web of Science ®Google Scholar
• Perkins C, Wills-Karp M, Finkelman FD. Il-4 induces il-13-independent allergic airway inflammation. J Allergy Clin Immunol 2006;118:410-19
   PubMed Web of Science ®Google Scholar
• Kasaian MT, Miller DK. Il-13 as a therapeutic target for respiratory disease. Biochem Pharmacol 2008;76:147-55
   PubMed Web of Science ®Google Scholar
• Batra V, Musani AI, Hastie AT, Bronchoalveolar lavage fluid concentrations of transforming growth factor (tgf)-beta1, tgf-beta2, interleukin (il)-4 and il-13 after segmental allergen challenge and their effects on alpha-smooth muscle actin and collagen iii synthesis by primary human lung fibroblasts. Clin Exp Allergy 2004;34:437-44
   PubMed Web of Science ®Google Scholar
• Prieto J, Lensmar C, Roquet A, Increased interleukin-13 mrna expression in bronchoalveolar lavage cells of atopic patients with mild asthma after repeated low-dose allergen provocations. Respir Med 2000;94:806-14
   PubMed Web of Science ®Google Scholar
• Catley MC, Coote J, Bari M, Tomlinson KL. Monoclonal antibodies for the treatment of asthma. Pharmacol Ther 2011;132:333-51
   PubMed Web of Science ®Google Scholar
• Perkins C, Wills-Karp M, Finkelman FD. Il-4 induces il-13–independent allergic airway inflammation. J Allergy Clin Immunol 2006;118:410-19
   PubMed Web of Science ®Google Scholar
• Gavett SH, O'Hearn DJ, Karp CL, Interleukin-4 receptor blockade prevents airway responses induced by antigen challenge in mice. Am J Physiol 1997;272:L253-61
   PubMed Web of Science ®Google Scholar
• Ma Y, HayGlass KT, Becker AB, Novel recombinant interleukin-13 peptide-based vaccine reduces airway allergic inflammatory responses in mice. Am J Respir Crit Care Med 2007;176:439-45
   PubMed Web of Science ®Google Scholar
• Bree A, Schlerman FJ, Wadanoli M, Il-13 blockade reduces lung inflammation after ascaris suum challenge in cynomolgus monkeys. J Allergy Clin Immunol 2007;119:1251-7
   PubMed Web of Science ®Google Scholar
• Kasaian MT, Tan XY, Jin M, Interleukin-13 neutralization by two distinct receptor blocking mechanisms reduces immunoglobulin e responses and lung inflammation in cynomolgus monkeys. J Pharmacol Exp Ther 2008;325:882-92
   PubMed Web of Science ®Google Scholar
• Kasaian MT, Raible D, Marquette K, Il-13 antibodies influence il-13 clearance in humans by modulating scavenger activity of il-13ralpha2. J Immunol 2011;187:561-9
   PubMed Web of Science ®Google Scholar
• Gauvreau GM, Boulet L-P, Cockcroft DW, Effects of interleukin-13 blockade on allergen-induced airway responses in mild atopic asthma. Am J Respir Crit Care Med 2011;183:1007-14
   PubMed Web of Science ®Google Scholar
• May RD, Monk PD, Cohen ES, Preclinical development of cat-354, an il-13 neutralizing antibody, for the treatment of severe uncontrolled asthma. Br J Pharmacol 2012;166:177-93
   PubMed Web of Science ®Google Scholar
• Piper E, Brightling C, Niven R, A phase 2 placebo-controlled study of tralokinumab in moderate-to-severe asthma. Eur Respir J 2012; [Epub ahead of print]
   Web of Science ®Google Scholar
• Corren J, Lemanske RF, Hanania NA, Lebrikizumab treatment in adults with asthma. N Engl J Med 2011;365:1088-98
   PubMed Web of Science ®Google Scholar
• Corren J, Busse W, Meltzer EO, A randomized, controlled, phase 2 study of amg 317, an il-4ralpha antagonist, in patients with asthma. Am J Respir Crit Care Med 2010;181:788-96
   PubMed Web of Science ®Google Scholar
• Temann UA, Geba GP, Rankin JA, Flavell RA. Expression of interleukin 9 in the lungs of transgenic mice causes airway inflammation, mast cell hyperplasia, and bronchial hyperresponsiveness. J Exp Med 1998;188:1307-20
   PubMed Web of Science ®Google Scholar
• Antoniu SA. Medi-528, an anti-il-9 humanized antibody for the treatment of asthma. Curr Opin Mol Ther 2010;12:233-9
   PubMed Web of Science ®Google Scholar
• Parker J, Oh C, LaForce C, Group tM-CT. Safety profile and clinical activity of multiple subcutaneous doses of medi-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma. BMC Pulm Med 2011;11:14
   PubMed Web of Science ®Google Scholar
• Howarth PH, Babu KS, Arshad HS, Tumour necrosis factor (tnfalpha) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 2005;60:1012-18
   PubMed Web of Science ®Google Scholar
• Erin EM, Leaker BR, Nicholson GC, The effects of a monoclonal antibody directed against tumor necrosis factor-alpha in asthma. Am J Respir Crit Care Med 2006;174:753-62
   PubMed Web of Science ®Google Scholar
• Wenzel SE, Barnes PJ, Bleecker ER, Investigators obotTA. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med 2009;179:549-58
   PubMed Web of Science ®Google Scholar
• Papp KA, Leonardi C, Menter A, Brodalumab, an anti–interleukin-17–receptor antibody for psoriasis. N Engl J Med 2012;366:1181-9
   PubMed Web of Science ®Google Scholar
• Suzukawa M, Morita H, Nambu A, Epithelial cell-derived il-25, but not th17 cell-derived il-17 or il-17f, is crucial for murine asthma. J Immunol 2012;189:3641-52
   PubMed Web of Science ®Google Scholar
• Petersen BC, Lukacs NW. Il-17a and il-25: Therapeutic targets for allergic and exacerbated asthmatic disease. Future Med Chem 2012;4:833-6
   PubMed Web of Science ®Google Scholar
• Holgate S, Smith N, Massanari M, Jimenez P. Effects of omalizumab on markers of inflammation in patients with allergic asthma. Allergy 2009;64:1728-36
   PubMed Web of Science ®Google Scholar
• Holgate ST, Chuchalin AG, Hebert J, Omalizumab 011 International Study G. Efficacy and safety of a recombinant anti-immunoglobulin e antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004;34:632-8
   PubMed Web of Science ®Google Scholar
• Holgate S, Buhl R, Bousquet J, The use of omalizumab in the treatment of severe allergic asthma: a clinical experience update. Respir Med 2009;103:1098-113
   PubMed Web of Science ®Google Scholar
• Poole JA, Meng J, Reff M, Anti-cd23 monoclonal antibody, lumiliximab, inhibited allergen-induced responses in antigen-presenting cells and t cells from atopic subjects. J Allergy Clin Immunol 2005;116:780-8
   PubMed Web of Science ®Google Scholar
• Brightbill HD, Jeet S, Lin Z, Antibodies specific for a segment of human membrane ige deplete ige-producing b cells in humanized mice. J Clin Invest 2010;120:2218-29
   PubMed Web of Science ®Google Scholar
• Scheerens HPW, Zheng Y, Wang Y, Treatment with memp1972a, an anti-m1 prime monoclonal antibody, reduced serum ige in healthy volunteers and patients with allergic rhinitis. Am J Respir Crit Care Med 2012;185:A6791
   Google Scholar
• Gauvreau GBL, Cockcroft DW, Davis B, Effect of an anti-m1 prime monoclonal antibody, memp1972a, in a phase ii proof-of-activity allergen challenge study in patients with mild asthma. Am J Respir Crit Care Med 2012;185:A6793
   Google Scholar
• Nakagami Y, Kawase Y, Yonekubo K, Rs-1748, a novel cc chemokine receptor 4 antagonist, inhibits ovalbumin-induced airway inflammation in guinea pigs. Biol Pharm Bull 2010;33:1067-9
   PubMed Web of Science ®Google Scholar
• Antoniu SA. Mogamulizumab, a humanized mab against c-c chemokine receptor 4 for the potential treatment of t-cell lymphomas and asthma. Curr Opin Mol Ther 2010;12:770-9
   PubMed Web of Science ®Google Scholar
• Willems LI, Ijzerman AP. Small molecule antagonists for chemokine ccr3 receptors. Med Res Rev 2010;30:778-817
   PubMed Web of Science ®Google Scholar
• Taha RA, Laberge S, Hamid Q, Olivenstein R. Increased expression of the chemoattractant cytokines eotaxin, monocyte chemotactic protein-4, and interleukin-16 in induced sputum in asthmatic patients. Chest 2001;120:595-601
   PubMed Web of Science ®Google Scholar
• Dent G, Hadjicharalambous C, Yoshikawa T, Contribution of eotaxin-1 to eosinophil chemotactic activity of moderate and severe asthmatic sputum. Am J Respir Crit Care Med 2004;169:1110-17
   PubMed Web of Science ®Google Scholar
• Bosnjak B, Stelzmueller B, Erb K, Epstein M. Treatment of allergic asthma: modulation of th2 cells and their responses. Respir Res 2011;12:114
   PubMedGoogle Scholar
• Bartemes KR, Kita H. Dynamic role of epithelium-derived cytokines in asthma. Clin Immunol 2012;143:222-35
   PubMed Web of Science ®Google Scholar
• Han H, Xu W, Headley MB, Thymic stromal lymphopoietin (tslp)-mediated dermal inflammation aggravates experimental asthma. Mucosal Immunol 2012;5:342-51
   PubMed Web of Science ®Google Scholar
• Shikotra A, Choy DF, Ohri CM, Increased expression of immunoreactive thymic stromal lymphopoietin in patients with severe asthma. J Allergy Clin Immunol 2012;129:104-11; e109
   PubMed Web of Science ®Google Scholar
• Shi L, Leu S-W, Xu F, Local blockade of tslp receptor alleviated allergic disease by regulating airway dendritic cells. Clin Immunol 2008;129:202-10
   PubMed Web of Science ®Google Scholar
• Kaur D, Brightling C. Ox40/ox40 ligand interactions in t-cell regulation and asthmaox40 asthma. Chest J 2012;141:494-9
   PubMed Web of Science ®Google Scholar
• Hoshino A, Tanaka Y, Akiba H, Critical role for ox40 ligand in the development of pathogenic th2 cells in a murine model of asthma. Eur J Immunol 2003;33:861-9
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Bradykinin and asthma. Thorax 1992;47:979-83
   PubMed Web of Science ®Google Scholar
• Christiansen SC, Proud D, Sarnoff RB, Elevation of tissue kallikrein and kinin in the airways of asthmatic subjects after endobronchial allergen challenge. Am Rev Respir Dis 1992;145:900-5
   PubMed Web of Science ®Google Scholar
• Sexton DJ, Chen T, Martik D, Specific inhibition of tissue kallikrein 1 with a human monoclonal antibody reveals a potential role in airway diseases. Biochem J 2009;422:383-92
   PubMed Web of Science ®Google Scholar
• Di Francia M, Barbier D, Mege JL, Orehek J. Tumor necrosis factor-alpha levels and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1994;150:1453-5
   PubMed Web of Science ®Google Scholar
• de Godoy I, Donahoe M, Calhoun WJ, Elevated tnf-alpha production by peripheral blood monocytes of weight-losing copd patients. Am J Respir Crit Care Med 1996;153:633-7
   PubMed Web of Science ®Google Scholar
• Takabatake N, Nakamura H, Abe S, The relationship between chronic hypoxemia and activation of the tumor necrosis factor-alpha system in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:1179-84
   PubMed Web of Science ®Google Scholar
• Garrod R, Marshall J, Barley E, The relationship between inflammatory markers and disability in chronic obstructive pulmonary disease (copd). Prim Care Respir J 2007;16:236-40
   PubMedGoogle Scholar
• Suissa S, Ernst P, Hudson M. Tnf-alpha antagonists and the prevention of hospitalisation for chronic obstructive pulmonary disease. Pulm Pharmacol Ther 2008;21:234-8
   PubMed Web of Science ®Google Scholar
• Rennard SI, Fogarty C, Kelsen S, The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175:926-34
   PubMed Web of Science ®Google Scholar
• van der Vaart H, Koeter GH, Postma DS, First study of infliximab treatment in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;172:465-9
   PubMed Web of Science ®Google Scholar
• Dhimolea E. Canakinumab. mAbs 2010;2:3-13
   PubMed Web of Science ®Google Scholar
• A study to evaluate the efficacy of medi8968 in chronic obstructive pulmonary disease (spring). NCT01448850. Available from: www.clinicaltrials.gov [Accessed on October 2012]
   Google Scholar
• Mahler DA, Huang S, Tabrizi M, Bell GM. Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in copd*a pilot study. Chest J 2004;126:926-34
   PubMed Web of Science ®Google Scholar
• Kubera JHK, Williams C, Hubeau C. Interleukin-6 neutralization abrogates acute exacerbation-like disease in a model of cigarette smoke-induced pulmonary inflammation. Am J Respir Crit Care Med 2012;185:A3876
   Google Scholar
• Shen N, Wang J, Zhao M, Anti-interleukin-17 antibodies attenuate airway inflammation in tobacco-smoke-exposed mice. Inhal Toxicol 2011;23:212-18
   PubMed Web of Science ®Google Scholar
• Kang M-J, Choi J-M, Kim BH, Il-18 induces emphysema and airway and vascular remodeling via ifn-gamma, il-17a, and il-13. Am J Respir Crit Care Med 2012;185:1205-17
   PubMed Web of Science ®Google Scholar
• Medi-2338. Available from: http://www.ncats.nih.gov/files/MEDI2338.pdf
   Google Scholar